Peapack Gladstone Financial Corp lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 734,965 shares of the biopharmaceutical company's stock after selling 28,011 shares during the quarter. Peapack Gladstone Financial Corp's holdings in Pfizer were worth $19,499,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. Ilmarinen Mutual Pension Insurance Co lifted its stake in shares of Pfizer by 48.8% in the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 982,000 shares of the biopharmaceutical company's stock worth $26,052,000 after buying an additional 322,000 shares during the last quarter. Russell Investments Group Ltd. grew its position in Pfizer by 2.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,798,470 shares of the biopharmaceutical company's stock worth $100,752,000 after purchasing an additional 73,526 shares during the last quarter. Rahlfs Capital LLC bought a new position in shares of Pfizer during the 4th quarter worth about $1,060,000. Hurley Capital LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $86,000. Finally, Ted Buchan & Co acquired a new stake in Pfizer during the fourth quarter worth about $700,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Price Performance
NYSE PFE traded down $1.30 on Friday, hitting $22.99. 79,829,399 shares of the company were exchanged, compared to its average volume of 39,460,357. Pfizer Inc. has a 1-year low of $22.95 and a 1-year high of $31.54. The firm has a 50 day moving average of $25.87 and a two-hundred day moving average of $26.72. The company has a market cap of $130.39 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Activity
In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of analysts have commented on the company. Bank of America reiterated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $31.92.
Get Our Latest Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
